Indian pharmaceutical companies have increased their expenditure in their research and development section by 19.7%. The purpose of this increment is not to discover new drugs but to create more cost effective generic drugs. More investment may make them a…
Conflicts between the innovators and generic companies have increased to a great extent and the latest example of the same is the one between Novartis and Merck-Glenmark. These conflicts came into picture when Mylan filed an Abbreviated New Drug Application…